dexamethasone,lenalidomide,isatuximab,carfilzomib
sanofi,amgen
[' ave ', 'gmmg-concept', 'concept trial', 'krd', 'light chain']
the gmmg-concept trial w/isa-krd for high risk mm. amazing that 45% had del17p! high mrd-neg (10^-5) rates for both transplant eligible and ineligible (68% and 54%). validates the approach of extended anti-cd38 + krd for high-risk. there may not be any shortcuts for hrmm! #ash22 
Asst Professor at University of Chicago, specializing in (vanquishing) plasma cell disorders. I tweet about: Myeloma & MRD. https://t.co/mPeWg1QRrW